Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 289, Issue 5 33-5, 2005, Pages

  Deruelle, Philippe ^a,b   Grover, Theresa R ^a   Abman, Steven H ^a,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIV LILLE   (France)

^c CHILDREN S HOSPITAL   (United States)

Author keywords

Direct soluble guanylate cyclase activator; Lung; Pulmonary hypertension of the newborn; Pulmonary vascular reactivity; Vasodilator

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCHOLINE; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; FETUS; HEMODYNAMICS; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; NEWBORN; NEWBORN DISEASE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SHEEP; VASODILATATION;

EID: 24644479957     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00119.2005     Document Type: Article

References (43)

1. Abman SH, Chatfield BA, Hall SL, and McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol Heart Circ Physiol 259: H1921-H1927, 1990.
2. Abman SH, Chatfield BA, Rodman DM, Hall SL, and McMurtry IF. Maturational changes in endothelium-derived relaxing factor activity of ovine pulmonary arteries in vitro. Am J Physiol Lung Cell Mol Physiol 260: L280-L285, 1991.
3. Abman SH, Shanley PF, and Accurso FJ. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 83: 1849-1858, 1989.
4. Abman SH, Wilkening RB, Ward RM, and Accurso FJ. Adaptation of fetal pulmonary blood flow to local infusion of tolazoline. Pediatr Res 20: 1131-1135, 1986.
5. Belik J, Keeley FW, Baldwin F, and Rabinovitch M. Pulmonary hypertension and vascular remodeling in fetal sheep. Am J Physiol Heart Circ Physiol 266: H2303-H2309, 1994.
6. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, and Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107: 686-689, 2003.
7. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, and Kinsella JP. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 342: 469-474, 2000.
8. Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, and Abman SH. Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am J Physiol Heart Circ Physiol 262: H1474-H1481, 1992.
9. Deruelle P, Grover TR, Storme L, and Abman SH. Effects of Bay 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 288: L727-L733, 2005.
10. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, and Zapol WM. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110: 2253-2259, 2004.
11. Friebe A and Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93: 96-105, 2003.
12. Hanson KA, Burns F, Rybalkin SD, Miller JW, Beavo J, and Clarke WR. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 158: 279-288, 1998.
13. Hanson KA, Ziegler JW, Rybalkin SD, Miller JW, Abman SH, and Clarke WR. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am J Physiol Lung Cell Mol Physiol 275: L931-L941, 1998.
14. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, Clark MW, Winkler JD, Bloch KD, and Zapol WM. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29: 1000-1005, 2001.
15. Kinsella JP and Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 126: 853-864, 1995.
16. Kinsella JP, Ivy DD, and Abman SH. Ontogeny of NO activity and response to inhaled NO in the developing ovine pulmonary circulation. Am J Physiol Heart Circ Physiol 267: H1955-H1961, 1994.
17. Kinsella JP, McQueston JA, Rosenberg AA, and Abman SH. Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation. Am J Physiol Heart Circ Physiol 263: H875-H880, 1992.
18. Konduri GG, Ou J, Shi Y, and Pritchard KA Jr. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 285: H204-H211, 2003.
19. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, and Rudolph AM. Persistent pulmonary hypertension of the newborn infant. J Pediatr 89: 626-630, 1976.
20. Lewis AB, Heymann MA, and Rudolph AM. Gestational changes in pulmonary vascular responses in fetal lambs in utero. Circ Res 39: 536-541, 1976.
21. Mayer B and Koesling D. cGMP signalling beyond nitric oxide. Trends Pharmacol Sci 22: 546-548, 2001.
22. McQueston JA, Cornfield DN, McMurtry IF, and Abman SH. Effects of oxygen and exogenous L-arginine on EDRF activity in fetal pulmonary circulation. Am J Physiol Heart Circ Physiol 264: H865-H871, 1993.
23. McQueston JA, Kinsella JP, Ivy DD, McMurtry IF, and Abman SH. Chronic pulmonary hypertension in utero impairs endothelium-dependent vasodilation. Am J Physiol Heart Circ Physiol 268: H288-H294, 1995.
24. Meyrick B. Structure function correlates in the pulmonary vasculature during acute lung injury and chronic pulmonary hypertension. Toxicol Pathol 19: 447-457, 1991.
25. Morin FC III. Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb. Pediatr Res 25: 245-250, 1989.
26. Mullershausen F, Russwurm M, Friebe A, and Koesling D. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109: 1711-1713, 2004.
27. Murphy JD, Rabinovitch M, Goldstein JD, and Reid LM. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 98: 962-967, 1981.
28. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336: 597-604, 1997.
29. Rairigh RL, Le Cras TD, Ivy DD, Kinsella JP, Richter G, Horan MP, Fan ID, and Abman SH. Role of inducible nitric oxide synthase in regulation of pulmonary vascular tone in the late gestation ovine fetus. J Clin Invest 101: 15-21, 1998.
30. Roberts JD Jr, Chen TY, Kawai N, Wain J, Dupuy P, Shimouchi A, Bloch K, Polaner D, and Zapol WM. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ Res 72: 246-254, 1993.
31. Roberts JD, Polaner DM, Lang P, and Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340: 818-819, 1992.
32. Sastry BK, Narasimhan C, Reddy NK, and Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43: 1149-1153, 2004.
33. Shaul PW, Yuhanna IS, German Z, Chen Z, Steinhorn RH, and Morin FC III. Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 272: L1005-L1012, 1997.
34. Sheehy AM, Burson MA, and Black SM. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: a role for superoxide. Am J Physiol Lung Cell Mol Physiol 274: L833-L841, 1998.
35. Shekerdemian LS, Ravn HB, and Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 55: 413-418, 2004.
36. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, and Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215, 2001.
37. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, and Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783, 2002.
38. Steinhorn RH, Russell JA, and Morin FC III. Disruption of cGMP production in pulmonary arteries isolated from fetal lambs with pulmonary hypertension. Am J Physiol Heart Circ Physiol 268: H1483-H1489, 1995.
39. Storme L, Rairigh RL, Parker TA, Kinsella JP, and Abman SH. In vivo evidence for a myogenic response in the fetal pulmonary circulation. Pediatr Res 45: 425-431, 1999.
40. Travadi JN and Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 36: 529-535, 2003.
41. Tzao C, Nickerson PA, Russell JA, Gugino SF, and Steinhorn RH. Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs. Pediatr Pulmonol 31: 97-105, 2001.
42. Villamor E, Le Cras TD, Horan MP, Halbower AC, Tuder RM, and Abman SH. Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 272: L1013-L1020, 1997.
43. Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch KD, and Zapol WM. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92: 1702-1712, 2000.